Thalidomide: An Old Drug with New Clinical Applications

REFERENCES

• Somers G.F. Pharmacological Properties of Thalidomide (Alpha-Phthalimido Glutamide), a New Sedative Hypnotic Drug. Br. J. Pharmacol. 1960; 15: 111–116
   PubMed Web of Science ®Google Scholar
• Lenz W. Malformations Caused by Drugs in Pregnancy. Am. J. Dis. Child 1966; 99–106
   PubMedGoogle Scholar
• Mcbride W.G. Thalidomide and Congenital Abnormalities. Lancet 1961; 2: 1358
   Web of Science ®Google Scholar
• Sheskin J. Thalidomide in the Treatment of Lepra Reaction. Clin. Pharmacol. Ther. 1965; 6: 303–306
   PubMed Web of Science ®Google Scholar
• Knop J., Macher E. Thalidomide Treatment of Chronic Discoid Lupus Erythematosus. Hautarzt 1983; 34: 435–436
   PubMed Web of Science ®Google Scholar
• Ordi-Ros J., Cortes F., Cucurull E., Mauri M., Bujan S., Vilardell M. Thalidomide in the Treatment of Cutaneous Lupus Refractory to Conventional Therapy. J. Rheumatol. 2000; 27: 1429–1433
   PubMed Web of Science ®Google Scholar
• Stevens R.J., Andujar C., Edwards C.J., Ames P.R., Barwick A.R., Khamashta M.A., Hughes G.R. Thalidomide in the Treatment of the Cutaneous Manifestations of Lupus Erythematosus: Experience in Sixteen Consecutive Patients. Br. J. Rheumatol. 1997; 36: 353–359
   PubMedGoogle Scholar
• Bahmer F.A., Zaun H., Luszpinski P. Thalidomide Treatment of Recurrent Erythema Multiforme. Acta Dermato-Venereol. 1982; 62: 449–450
   PubMed Web of Science ®Google Scholar
• Cherouati K., Claudy A., Souteyrand P., Cambazard F., Vaillant L., Moulin G., Crickx B., Morel P., Lamorelle A., Revuz J. Treatment by Thalidomide of Chronic Multiforme Erythema: Its Recurrent and Continuous Variants. A Retrospective Study of 26 Patients. Ann. Dermato-Venereol. 1996; 123: 375–377
   PubMed Web of Science ®Google Scholar
• Johnke H., Zachariae H. Thalidomide Treatment of Prurigo Nodularis. Ugeskr Laeger 1993; 155: 3028–3030
   PubMedGoogle Scholar
• DeVincenzo J.P., Burchet S.K. Prolonged Thalidomide Therapy for Human Immunodeficiency Virus-Associated Recurrent Severe Esophageal and Oral Aphthous Ulcers. Pediatr. Infect. Dis. J. 1996; 15: 465–467
   PubMed Web of Science ®Google Scholar
• Jacobson J.M., Spritzler J., Fox L., Fahey J.L., Jackson J.B., Chernoff M., Wohl D.A., Wu A.W., Hooton T.M., Sha B.E., Shikuma C.M., MacPhail L.A., Simpson D.M., Trapnell C.B., Basgoz N. Thalidomide for the Treatment of Esophageal Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J. Infect. Dis. 1999; 180: 61–67
   PubMed Web of Science ®Google Scholar
• Ramirez-Amador V.A., Esquivel-Pedraza L., Ponce-de-Leon S., Reyes-Teran G., Gonzalez-Guevara M., Sierra-Madero J.G. Thalidomide as Therapy for Human Immunodeficiency Virus-Related Oral Ulcers: A Double-Blind Placebo-Controlled Clinical Trial. Clin. Infect. Dis. 1999; 28: 892–894
   PubMed Web of Science ®Google Scholar
• Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., Zwingenberger K., Yazici H. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Intern. Med. 1998; 128: 443–450
   PubMed Web of Science ®Google Scholar
• Hamza M.H. Treatment of Behcet's Disease with Thalidomide. Clin. Rheumatol. 1986; 5: 365–371
   PubMed Web of Science ®Google Scholar
• Mangelsdorf H.C., White W.L., Jorizzo J.L. Behcet's Disease. Report of Twenty-Five Patients from the United States with Prominent Mucocutaneous Involvement. J. Am. Acad. Dermatol. 1996; 34: 745–750
   PubMed Web of Science ®Google Scholar
• Waters M.F., Laing A.B., Ambikapathy A., Lennard-Jones J.E. Treatment of Ulcerative Colitis with Thalidomide. Br. Med. J. 1979; 1: 792
   PubMed Web of Science ®Google Scholar
• Gutierrez-Rodriguez O., Starusta-Bacal P., Gutierrez-Montes O. Treatment of Refractory Rheumatoid Arthritis: The Thalidomide Experience. J. Rheumatol. 1989; 16: 158–163
   PubMed Web of Science ®Google Scholar
• Gutierrez-Rodriguez O. Thalidomide. A Promising New Treatment for Rheumatoid Arthritis. Arthritis Rheum. 1984; 27: 1118–1121
   PubMed Web of Science ®Google Scholar
• Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., Calvieri S. Treatment of Cutaneous and Pulmonary Sarcoidosis with Thalidomide. J. Am. Acad. Dermatol. 1995; 32: 866–869
   PubMed Web of Science ®Google Scholar
• Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., Corio R.L., Levin L.S., Colvin O.M., Wingard J.R., Santos G. Thalidomide for the Treatment of Chronic Graft-versus-Host Disease. N. Engl. J. Med. 1992; 326: 1055–1058
   PubMed Web of Science ®Google Scholar
• Parker P.M., Chao N., Nademanee A., O'Donnell M.R., Schmidt G.M., Snyder D.S., Stein A.S., Smith E.P., Molina A., Stepan D.E., Kashyap A., Planas I., Spielberger R., Somlo G., Margolin K., Zwingenberger K., Wilsman K., Negrin R.S., Long G.D., Niland J.C., Blume K.G., Forman S.J. Thalidomide as Salvage Therapy for Chronic Graft-versus-Host Disease. Blood 1995; 86: 3604–3609
   PubMed Web of Science ®Google Scholar
• Rovelli A., Arrigo C., Nesi F., Balduzzi A., Nicolini B., Locasciulli A., Vassallo E., Miniero R., Uderzo C. The Role of Thalidomide in the Treatment of Refractory Chronic Graft-versus-Host Disease Following Bone Marrow Transplantation in Children. Bone Marrow Transplant. 1998; 21: 577–581
   PubMed Web of Science ®Google Scholar
• Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., Barlogie B. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N. Engl. J. Med. 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Fine H.A., Figg W.D., Jaeckle K., Wen P.Y., Kyritsis A.P., Loeffler J.S., Levin V.A., Black P.M., Kaplan R., Pluda J.M., Yung W.K. Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients with Recurrent High-Grade Gliomas. J. Clin. Oncol. 2000; 18: 708–715
   PubMed Web of Science ®Google Scholar
• Little R.F., Wyvill K.M., Pluda J.M., Welles L., Marshall V., Figg W.D., Newcomb F.M., Tosato G., Feigal E., Steinberg S.M., Whitby D., Goedert J.J., Yarchoan R. Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. J. Clin. Oncol. 2000; 18: 2593–2602
   PubMed Web of Science ®Google Scholar
• Davey P.P., Ashrafian H. New Therapies for Heart Failure: Is Thalidomide the Answer?. Q. J. Med. 2000; 93: 305–311
   Google Scholar
• Monastirli A., Georgiou S., Bolsen K., Pasmatzi E., Papapanagiotou A., Goerz G., Kalofoutis A., Merk H.F., Tsambaos D. Treatment of Porphyria Cutanea Tarda with Oral Thalidomide. Skin Pharmacol. Appl. Skin Physiol. 1999; 12: 305–311
   PubMedGoogle Scholar
• Spraul C.W., Kaven C.K., Kampmeier J.K., Lang G.K., Lang G.E. Effect of Thalidomide, Octreotide, and Prednisolone on the Migration and Proliferation of RPE Cells In Vitro. Curr. Eye Res. 1999; 19: 483–490
   PubMed Web of Science ®Google Scholar
• Fine S.L., Berger J.W., Maguire M.G., Ho A.C. Age-Related Macular Degeneration. N. Engl. J. Med. 2000; 342: 483–492
   PubMed Web of Science ®Google Scholar
• Verougstraete C. Present and Future Treatment of Age-Related Macular Degeneration. Bull. Soc. Belge Ophtalmol. 1999; 273: 79–101
   PubMedGoogle Scholar
• Schumacher H., Smith R.L., Williams R.T. The Metabolism of Thalidomide: The Spontaneous Hydrolysis of Thalidomide in Solution. Br. J. Pharmacol. 1965; 25: 324–337
   PubMed Web of Science ®Google Scholar
• Schumacher H., Smith R.L., Williams R.T. The Metabolism of Thalidomide: The Fate of Thalidomide and Some of Its Hydrolysis Products in Various Species. Br. J. Pharmacol. 1965; 25: 338–351
   PubMed Web of Science ®Google Scholar
• Fabro S., Smith R.L., Williams R.T. The Fate of the Hydrolysis Products of Thalidomide in the Pregnant Rabbit. Biochem. J. 1967; 104: 570–574
   PubMed Web of Science ®Google Scholar
• Wells P.G., Kim P.M., Laposa R.R., Nicol C.J., Parman T., Winn L.M. Oxidative Damage in Chemical Teratogenesis. Mutat. Res. 1997; 396: 65–78
   PubMed Web of Science ®Google Scholar
• Parman T., Wiley M.J., Wells P.G. Free Radical-Mediated Oxidative DNA Damage in the Mechanism of Thalidomide Teratogenicity. Nat. Med. 1999; 5: 582–585
   PubMed Web of Science ®Google Scholar
• Eriksson T., Bjorkman S., Roth B., Fyge A., Hoglund P. Stereospecific Determination, Chiral Inversion In Vitro and Pharmacokinetics in Humans of the Enantiomers of Thalidomide. Chirality 1995; 7: 44–52
   PubMed Web of Science ®Google Scholar
• Eriksson T., Bjorkman S., Roth B., Hoglund P. Intravenous Formulations of the Enantiomers of Thalidomide: Pharmacokinetic and Initial Pharmacodynamic Characterization in Man. J. Pharm. Pharmacol. 2000; 52: 807–817
   PubMed Web of Science ®Google Scholar
• Chen T.L., Vogelsang G.B., Petty B.G., Brundrett R.B., Noe D.A., Santos G.W., Colvin O.M. Plasma Pharmacokinetics and Urinary Excretion of Thalidomide After Oral Dosing in Healthy Male Volunteers. Drug Metab. Dispos. 1989; 17: 402–405
   PubMed Web of Science ®Google Scholar
• Piscitelli S.C., Figg W.D., Hahn B., Kelly G., Thomas S., Walker R.E. Single-Dose Pharmacokinetics of Thalidomide in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 1997; 41: 2797–2799
   PubMed Web of Science ®Google Scholar
• Figg W.D., Raje S., Bauer K.S., Tompkins A., Venzon D., Bergan R., Chen A., Hamilton M., Pluda J., Reed E. Pharmacokinetics of Thalidomide in an Elderly Prostate Cancer Population. J. Pharm. Sci. 1999; 88: 121–125
   PubMed Web of Science ®Google Scholar
• Baidas S.M., Winer E.P., Fleming G.F., Harris L., Pluda J.M., Crawford J.G., Yamauchi H., Isaacs C., Hanfelt J., Tefft M., Flockhart D., Johnson M.D., Hawkins M.J., Lippman M.E., Hayes D.F. Phase II Evaluation of Thalidomide in Patients with Metastatic Breast Cancer. J. Clin. Oncol. 2000; 18: 2710–2717
   PubMed Web of Science ®Google Scholar
• Teo S.K., Colburn W.A., Thomas S.D. Single-Dose Oral Pharmacokinetics of Three Formulations of Thalidomide in Healthy Male Volunteers. J. Clin. Pharmacol. 1999; 39: 1162–1168
   PubMed Web of Science ®Google Scholar
• Bauer K.S., Dixon S.C., Figg W.D. Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-Dependent. Biochem. Pharmacol. 1998; 55: 1827–1834
   PubMed Web of Science ®Google Scholar
• Eriksson T., Bjorkman S., Roth B., Bjork H., Hoglund P. Hydroxylated Metabolites of Thalidomide: Formation In-Vitro and In-Vivo in Man. J. Pharm. Pharmacol. 1998; 50: 1409–1416
   PubMed Web of Science ®Google Scholar
• Teo S.K., Sabourin P.J., O'Brien K., Kook K.A., Thomas S.D. Metabolism of Thalidomide in Human Microsomes, Cloned Human Cytochrome P-450 Isozymes, and Hansen's Disease Patients. J. Biochem. Mol. Toxicol. 2000; 14: 140–147
   PubMed Web of Science ®Google Scholar
• Trapnell C.B., Donahue S.R., Collins J.M., Flockhart D.A., Thacker D., Abernethy D.R. Thalidomide Does Not Alter the Pharmacokinetics of Ethinyl Estradiol and Norethindrone. Clin. Pharmacol. Ther. 1998; 64: 597–602
   PubMed Web of Science ®Google Scholar
• Scheffler M.R., Colburn W., Kook K.A., Thomas S.D. Thalidomide Does Not Alter Estrogen–Progesterone Hormone Single Dose Pharmacokinetics. Clin. Pharmacol. Ther. 1999; 65: 483–490
   PubMed Web of Science ®Google Scholar
• Stephens T.D. Proposed Mechanisms of Action in Thalidomide Embryopathy. Teratology 1988; 38: 229–239
   PubMedGoogle Scholar
• Stephens T.D., Bunde C.J., Fillmore B.J. Mechanism of Action in Thalidomide Teratogenesis. Biochem. Pharmacol. 2000; 59: 1489–1499
   PubMed Web of Science ®Google Scholar
• Sauer H., Gunther J., Hescheler J., Wartenberg M. Thalidomide Inhibits Angiogenesis in Embryoid Bodies by the Generation of Hydroxyl Radicals. Am. J. Pathol. 2000; 156: 151–158
   PubMed Web of Science ®Google Scholar
• Klausner J.D., Freedman V.H., Kaplan G. Thalidomide as an Anti-TNF-Alpha Inhibitor: Implications for Clinical Use. Clin. Immunol. Immunopathol. 1996; 81: 219–223
   PubMedGoogle Scholar
• Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide Exerts Its Inhibitory Action on Tumor Necrosis Factor Alpha by Enhancing mRNA Degradation. J. Exp. Med. 1993; 177: 1675–1680
   PubMed Web of Science ®Google Scholar
• Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes. J. Exp. Med. 1991; 173: 699–703
   PubMed Web of Science ®Google Scholar
• Rowland T.L., McHugh S.M., Deighton J., Dearman R.J., Ewan P.W., Kimber I. Differential Regulation by Thalidomide and Dexamethasone of Cytokine Expression in Human Peripheral Blood Mononuclear Cells. Immunopharmacology 1998; 40: 11–20
   PubMed Web of Science ®Google Scholar
• Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset. J. Exp. Med. 1998; 187: 1885–1892
   PubMed Web of Science ®Google Scholar
• Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., Patterson R.T., Stirling D.I., Kaplan G. Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-alpha. J. Immunol. 1999; 163: 380–386
   PubMed Web of Science ®Google Scholar
• Nogueira A.C., Neubert R., Helge H., Neubert D. Thalidomide and The Immune System. 3. Simultaneous Up- and Down-Regulation of Different Integrin Receptors on Human White Blood Cells. Life Sci. 1994; 55: 77–92
   PubMed Web of Science ®Google Scholar
• Geitz H., Handt S., Zwingenberger K. Thalidomide Selectively Modulates the Density of Cell Surface Molecules Involved in the Adhesion Cascade. Immunopharmacology 1996; 31: 213–221
   PubMed Web of Science ®Google Scholar
• Neubert R., Hinz N., Thiel R., Neubert D. Down-Regulation of Adhesion Receptors on Cells of Primate Embryos as a Probable Mechanism of the Teratogenic Action of Thalidomide. Life Sci. 1996; 58: 295–316
   PubMed Web of Science ®Google Scholar
• D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide Is an Inhibitor of Angiogenesis. Proc. Natl Acad. Sci. USA 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Kruse F.E., Joussen A.M., Rohrschneider K., Becker M.D., Volcker H.E. Thalidomide Inhibits Corneal Angiogenesis Induced by Vascular Endothelial Growth Factor. Graefes Arch. Clin. Exp. Ophthalmol. 1998; 236: 461–466
   PubMed Web of Science ®Google Scholar
• Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., Johnston S.R., Ahern R., Smith I.E., Gore M.E. Continuous Low Dose Thalidomide: A Phase II Study in Advanced Melanoma, Renal Cell, Ovarian and Breast Cancer. Br. J. Cancer 2000; 82: 812–817
   PubMed Web of Science ®Google Scholar
• Vredenburgh, J.; Long, G.; Blackwell, K.; Rizzieri, D.; Smith, C.; Petros, W.; Lewis, B.; Chao, N. In Thalidomide Modulates Vascular Endothelial Growth Factor (VEGF) Levels Post-autologous Peripheral Blood Progenitor Cell Transplantation in Patients with Metastatic Breast Cancer, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000; Vol. 19, No. 599.
   Google Scholar
• Jacobson J.M., Greenspan J.S., Spritzler J., Ketter N., Fahey J.L., Jackson J.B., Fox L., Chernoff M., Wu A.W., MacPhail L.A., Vasquez G.J., Wohl D.A. Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 1997; 336: 1487–1493
   PubMed Web of Science ®Google Scholar
• Sampaio E.P., Kaplan G., Miranda A., Nery J.A., Miguel C.P., Viana S.M., Sarno E.N. The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum. J. Infect. Dis. 1993; 168: 408–414
   PubMed Web of Science ®Google Scholar
• Tramontana J.M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J.D., Rom W., Kaplan G. Thalidomide Treatment Reduces Tumor Necrosis Factor Alpha Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis. Mol. Med. 1995; 1: 384–397
   PubMed Web of Science ®Google Scholar
• Zeldis J.B., Williams B.A., Thomas S.D., Elsayed M.E. S.T.E.P.S.: A Comprehensive Program for Controlling and Monitoring Access to Thalidomide. Clin. Ther. 1999; 21: 319–330
   PubMed Web of Science ®Google Scholar
• Kelsey F.O. Thalidomide Update: Regulatory Aspects. Teratology 1988; 38: 221–226
   PubMedGoogle Scholar
• Fullerton P.M., Kremer M. Neuropathy After Intake of Thalidomide. Br. Med. J. 1961; 855–858
   PubMed Web of Science ®Google Scholar
• Fullerton P.M., O'Sullivan D.J. Thalidomide Neuropathy: A Clinical Electrophysiological, and Histological Follow-Up Study. J. Neurol. Neurosurg. Psychiatry 1968; 31: 543–551
   PubMed Web of Science ®Google Scholar
• Elad S., Galili D., Garfunkel A.A., Or R. Thalidomide-Induced Perioral Neuropathy. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1997; 84: 362–364
   PubMed Web of Science ®Google Scholar
• Ochonisky S., Verroust J., Bastuji-Garin S., Gherardi R., Revuz J. Thalidomide Neuropathy Incidence and Clinico-electrophysiologic Findings in 42 Patients. Arch. Dermatol. 1994; 130: 66–69
   PubMed Web of Science ®Google Scholar
• Chapon F., Lechevalier B., da Silva D.C., Rivrain Y., Dupuy B., Deschamps P. Neuropathies Caused by Thalidomide. Rev. Neurol. 1985; 141: 719–728
   PubMedGoogle Scholar
• Hess C.W., Hunziker T., Kupfer A., Ludin H.P. Thalidomide-Induced Peripheral Neuropathy. A Prospective Clinical, Neurophysiological and Pharmacogenetic Evaluation. J. Neurol. 1986; 233: 83–89
   PubMed Web of Science ®Google Scholar
• Horowitz S.B., Stirling A.L. Thalidomide-Induced Toxic Epidermal Necrolysis. Pharmacotherapy 1999; 19: 1177–1180
   PubMed Web of Science ®Google Scholar
• Rajkumar S.V., Gertz M.A., Witzig T.E. Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma [Letter]. N. Engl. J. Med. 2000; 343: 972–973
   PubMed Web of Science ®Google Scholar
• Olson K., Chao N., Nademanee A., et al. Thalidomide (N-phthaloylglutamide) in the Treatment of Advanced Cancer. Clin. Pharmacol. Ther. 1965; 6: 292–297
   PubMed Web of Science ®Google Scholar
• Grabstald H., Golbey R. Clinical Experience with Thalidomide in Patients with Cancer. Clin. Pharmacol. Ther. 1965; 6: 298–302
   PubMed Web of Science ®Google Scholar
• Marx, G.; McCowatt, S.; Boyle, F.; Pavlakis, N.; Levi, J.; Bell, D.; Freilich, R.; Cook, R.; Biggs, M.; Little, N.; Wheeler, H. In Phase II Study of Thalidomide as An Antiangiogenic Agent in the Treatment of Recurrent Glioblastom Multiforme, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000; Vol. 19, No. 613.
   Google Scholar
• Glass, J.; Gruber, M.; Nirenberg, A. In Phase I/II Study of Carboplatin and Thaldiomide in Recurrent Glioblastoma Multiforme, Proceedings of American Society of Clinical Oncology, Atlanta, GA, May 15–18, 1999; Vol. 18, No. 551.
   Google Scholar
• Figg, W. In Randomized Phase II Study of Thalidomide in Androgen-Independent Prostate Cancer, Fall 1988 NCI Phase I Meeting, 1998.
   Google Scholar
• Barlogie, B. In Thalidomide in the Management of Multiple Myeloma: The Arkansas Experience in more than 300 Patients with Single Agent and Combination Chemotherapy, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000; Vol. 19, No. 28.
   Google Scholar
• Srkalovic, G.; Karam, A.; Trebisky, B.; Hussein, M. In Treatment of Refractory/Relapsed Multiple Myeloma with Combination of Melphalan, Thalidomide and Decadrone, Proceedings of American Society of Hematology, San Francisco, CA, 2000; Dec 1–5, No. 5016.
   Google Scholar
• Kropff, M.; Innig, G.; Mitterer, M.; Straka, C.; Ostermann, H.; Koch, O.; Berdel, W.; Kienast, J. In Hyperfractionated Cyclophosphamide in Combination with Pulsed Dexamethasone and Thalidomide in Primary Refractory or Relapsed Multiple Myeloma, Proceedings of American Society of Hematology, San Francisco, CA, Dec 1–5, 2000; No. 725.
   Google Scholar
• Coleman, M.; Leonard, J. In Clarithromycin, Low Dose Thalidomide and Dexamethasone Produces Consistent Response in Myeloma and Waldenstrom's Macroglobulinemia, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–30, 2000; Vol. 19, No. 27.
   Google Scholar
• Dimopoulos, M.; Viniou, N.; Zomas, A.; Galani, E.; Grigoraki, V.; Matsouka, C.; Economou, O.; Papadimitriou, C. In Activity of Thaldomide in Waldenstrom's Macroglobulinemia, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–30, 2000; Vol. 19, No. 99.
   Google Scholar
• Lisak, L.; Little, L.; Dean, L.; Ekbal, M.; DuRandt, M.; Hussain, M.; Kaistha, A.; Raza, A. In Delayed Response to Thalidomide in Patients with Myelodysplastic Syndromes, Proceedings of American Society of Hematology, San Francisco, CA, Dec 1–5, 2000; No. 4861.
   Google Scholar
• Raza, A.; Lisak, L.; Little, L.; Ekbal, M.; DuRant, M.; Ali, E.; Nascimben, F.; Tareen, M.; Venugopal, P. In Thalidomdie as a Single Agent or in Combination with Topotecan, Pentoxifyllin and/or Enbrel in Myelodysplastic Syndromes, Proceedings of American Society of Hematology, San Francisco, CA, Dec 1–5, 2000; No. 627.
   Google Scholar
• Canepa, L.; Ballerini, F.; Varaldo, R.; Grasso, R.; Clavio, M.; Miglino, M.; Pierri, I.; Gobbi, M. In Myelofibrosis: Report of Five Cases Treated with Thalidomide, Proceedings of American Society of Hematolgy, San Francisco, CA, Dec 1–5, 2000; No. 4886.
   Google Scholar
• Patt, Y.; Hassan, M.; Lozano, R.; Zeldis, J.; Schnirer, I.; Frome, A.; Abbruzzese, J.; Wolff, R.; Brown, T.; Ellis, L.; Charnsangavej, C. In Phase II Trial of Thalidomide for Treatment of Nonresetable Hepatocellular Carcinoma, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000; Vol. 19, No. 1035.
   Google Scholar
• Govindarajan R. Irinotecan and Thalidomide in Metastatic Colorectal Cancer. Oncology 2000; 14: 29–32
   PubMed Web of Science ®Google Scholar
• Hwu W. New Approaches in the Treatment of Metastatic Melanoma: Thalidomide and Temozolomide. Oncology 2000; 14: 25–28
   PubMed Web of Science ®Google Scholar
• Tseng, J.; Glisson, B.; Khuri, F.; Teddy, S.; Shin, D.; Gillenwater, A.; Myers, J.; Clayman, G.; El-Naggar, A.; Fritsche, H.; Lawhorn, K.; Thall, P.; Liu, D.; Herbst R. In Phase II of Thalidomide in the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck, Proceedings of American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000; Vol. 19, No. 1645.
   Google Scholar
• Mascaro J.M., Lecha M., Torras H. Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis [Letter]. Arch. Dermatol. 1979; 115: 636–637
   PubMed Web of Science ®Google Scholar
• Torras H., Lecha M., Mascaro J.M. Thalidomide Treatment of Recurrent Necrotic Giant Mucocutaneous Aphthae and Aphthosis [Letter]. Arch. Dermatol. 1982; 118: 875
   PubMed Web of Science ®Google Scholar
• Ryan J., Colman J., Pedersen J. Thalidomide to Treat Esophageal Ulcer in AIDS [Letter]. N. Engl. J. Med. 1992; 327: 208–209
   PubMed Web of Science ®Google Scholar
• Bowers P.W., Powell R.J. Effect of Thalidomide on Orogenital Ulceration. Br. Med. J. (Clin. Res. Ed.) 1983; 287: 799–800
   PubMed Web of Science ®Google Scholar
• Jenkins J.S., Powell R.J., Allen B.R., Littlewood S.M., Maurice P.D., Smith N.J. Thalidomide in Severe Orogenital Ulceration. Lancet 1984; 2: 1424–1426
   PubMed Web of Science ®Google Scholar
• Kurkcuoglu N., Atakan N., Eksioglu M. Thalidomide in the Treatment of Recurrent Necrotic Mucocutaneous Aphthae [Letter]. Br. J. Dermatol. 1985; 112: 632
   PubMed Web of Science ®Google Scholar
• Grinspan D. Significant Response of Oral Aphthosis to Thalidomide Treatment. J. Am. Acad. Dermatol. 1985; 12: 85–90
   PubMed Web of Science ®Google Scholar
• Revuz J., Guillaume J.C., Janier M., Hans P., Marchand C., Souteyrand P., Bonnetblanc J.M., Claudy A., Dallac S., Klene C., et al. Crossover Study of Thalidomide Vs Placebo in Severe Recurrent Aphthous Stomatitis. Arch. Dermatol. 1990; 126: 923–927
   PubMed Web of Science ®Google Scholar
• Iyer C.G., Languillon J., Ramanujam K., Tarabini-Castellani G., De las Aguas J.T., Bechelli L.M., Uemura K., Martinez Dominguez V., Sundaresan T. WHO Co-ordinated Short-Term Double-Blind Trial with Thalidomide in the Treatment of Acute Lepra Reactions in Male Lepromatous Patients. Bull. WHO 1971; 45: 719–732
   PubMed Web of Science ®Google Scholar
• Knop J., Bonsmann G., Happle R., Ludolph A., Matz D.R., Mifsud E.J., Macher E. Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus. Br. J. Dermatol. 1983; 108: 461–466
   PubMed Web of Science ®Google Scholar
• Kyriakis K.P., Kontochristopoulos G.J., Panteleos D.N. Experience with Low-Dose Thalidomide Therapy in Chronic Discoid Lupus Erythematosus. Int. J. Dermatol. 2000; 39: 218–222
   PubMed Web of Science ®Google Scholar
• Jorizzo J.L., Schmalstieg F.C., Solomon A.R., Jr, Cavallo T., Taylor R.S.d., Rudloff H.B., Schmalstieg E.J., Daniels J.C. Thalidomide Effects in Behcet's Syndrome and Pustular Vasculitis. Arch. Intern. Med. 1986; 146: 878–881
   PubMed Web of Science ®Google Scholar
• Sheskin J. Therapeutic Experience on the Effect of Thalidomide on Lepra Reaction. Hautarzt 1975; 26: 1–5
   PubMed Web of Science ®Google Scholar
• van den Broek H. Treatment of Prurigo Nodularis with Thalidomide. Arch. Dermatol. 1980; 116: 571–572
   PubMed Web of Science ®Google Scholar
• Reyes-Teran G., Sierra-Madero J.G., Martinez del Cerro V., Arroyo-Figueroa H., Pasquetti A., Calva J.J., Ruiz-Palacios G.M. Effects of Thalidomide on HIV-Associated Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. AIDS 1996; 10: 1501–1507
   PubMed Web of Science ®Google Scholar
• Kaplan, G.; Schambelau, M.; Gottleib, M. In Thalidomide Reverses Cachexia in HIV-Wasting Syndrome, Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998.
   Google Scholar
• Sharpstone D., Rowbottom A., Francis N., Tovey G., Ellis D., Barrett M., Gazzard B. Thalidomide: A Novel Therapy for Microsporidiosis. Gastroenterology 1997; 112: 1823–1829
   PubMed Web of Science ®Google Scholar
• Heney D., Norfolk D.R., Wheeldon J., Bailey C.C., Lewis I.J., Barnard D.L. Thalidomide Treatment for Chronic Graft-versus-Host Disease. Br. J. Haematol. 1991; 78: 23–27
   PubMed Web of Science ®Google Scholar
• Wettstein A.R., Meagher A.P. Thalidomide in Crohn's Disease. Lancet 1997; 350: 1445–1446
   PubMed Web of Science ®Google Scholar
• Odeka E.B., Miller V. Thalidomide in Oral Crohn's Disease Refractory to Conventional Medical Treatment. J. Pediatr. Gastroenterol. Nutr. 1997; 25: 250–251
   Web of Science ®Google Scholar
• De Cock K.M. Treatment of Ulcerative Colitis. Br. Med. J. 1979; 1: 1356, (letter)
   PubMed Web of Science ®Google Scholar
• Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., Hanauer S.B. Thalidomide Therapy for Patients with Refractory Crohn's Disease: An Open-Label Trial. Gastroenterology 1999; 117: 1271–1277
   PubMed Web of Science ®Google Scholar
• Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., Hassard P.V., Papadakis K.A., Yang H., Zeldis J.B., Targan S.R. An Open-Label Pilot Study of Low-Dose Thalidomide in Chronically Active, Steroid-Dependent Crohn's Disease. Gastroenterology 1999; 117: 1278–1287
   PubMed Web of Science ®Google Scholar
• Schoeman J.F., Springer P., Ravenscroft A., Donald P.R., Bekker L.G., van Rensburg A.J., Hanekom W.A., Haslett P.A., Kaplan G. Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-inflammatory Role. J. Child Neurol. 2000; 15: 497–503
   PubMed Web of Science ®Google Scholar